Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial 06 / 02 / 24| Read More
The spin-off Peptomyc and VHIO awarded €4 million from the Spanish Ministry of Science and Innovation to advance the clinical development of the first direct MYC inhibitor 20 / 12 / 23| Read More
Peptomyc announces first patient dosed in Phase Ib trial of OMO-103 in combination with standard of care chemotherapy in first-line metastatic PDAC patients 28 / 11 / 23| Read More
Peptomyc is awarded €5 million from the Horizon Europe EIC Accelerator Program to conduct a Phase 1b clinical trial with OMO-103 in patients and scale up its manufacturing process 31 / 10 / 23| Read More
Peptomyc announces the approval of its Phase 1b trial testing OMO-103 in combination with standard of care in PDAC patients 27 / 07 / 23| Read More
Results from phase I clinical trial of the first drug to successfully inhibit the MYC protein, which drives many common cancers 01 / 11 / 22| Read More
Omomyc as the first MYC-targeted therapy to successfully complete a phase I clinical trial 28 / 10 / 22| Read More
TODAY in El Mundo: “Así avanza el fármaco español pionero en su estrategia contra el cáncer” 26 / 10 / 22| Read More
TODAY in La Vanguardia: “Èxit del primer assaig en pacients del fàrmac Omomyc contra el càncer” 26 / 10 / 22| Read More
